<dfn id="bx7w9"></dfn>
| 產品名稱 | NCI-H82 [H82] |
|---|---|
| 商品貨號 | B198991 |
| Organism | Homo sapiens, human |
| Tissue | lung; derived from metastatic site: pleural effusion |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | aggregates in suspension; the cells grow in very large aggregates, and the aggregates are the only viable cell population |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | carcinoma; small cell lung cancer |
| Age | 40 years |
| Gender | male |
| Ethnicity | Caucasian |
| Karyotype | This is a near triploid human cell line. The modal chromosome number is 58, occurring at 44% with polyploidy at 3%. Marker chromosomes der(1)t(1;709p13;p11), t(13q;?HSR;15q) and der(190t(19;?)(q13.4;?) were common to most cells., There were two distinct subpopulations readily distinguished by karyotype. Besides uniform changes in the numbers of copies of some normal chromosomes, one population had der(3)t(3;20)(p11;p11?), t(3q19p), i(7q) and a minute chromosome of unknown origin., The other had t(1q17p), del(1)(q21), der(3)t(3;7)(p12;q11) plus two other markers. Each cell had two copies of a normal X chromosome. The Y chromosome was not detected in Q banded preparations. |
| Derivation | The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung. Derived from metastatic site, pleural effusion |
| Clinical Data | 40 years Caucasian male The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung. |
| Receptor Expression | Insulin-like growth factor II (IGF II); atrial natriuretic peptide (ANP) |
| Oncogene | myc +; myb -; raf +; ras +; fms +; fes + |
| Tumorigenic | Yes |
| Effects | Yes, in nude mice |
| Comments | The morphology of the original tumor was not characteristic of SCLC.
The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase.
It does not have detectable levels of L-DOPA decarboxylase or bombesin.
The cells produce an abnormally sized p53 mRNA (3.7 kb).
C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells.
The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern.
The cells stain positively for neurofilaments and vimentin.
There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs.
|
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | This line grows as aggregates of cells in suspension. Culture can be maintained by addition of medium or by replacement of medium. Alternatively, the cells may be collected by centrifugation and dispersed into fresh medium.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation | Culture medium, 95%; DMSO, 5% |
| Culture Conditions | Temperature: 37°C |
| STR Profile | Amelogenin: X CSF1PO: 11 D13S317: 8 D16S539: 12 D5S818: 12 D7S820: 10,13 THO1: 9,9.3 TPOX: 11 vWA: 14 |
| Isoenzymes | AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1 Me-2, 1 PGM1, 1-2 PGM3, 1-2 |
| Name of Depositor | AF Gazdar, JD Minna |
| Deposited As | Homo sapiens |
| Year of Origin | 1978 |
| References | Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201 Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024 The cells form transplantable tumors with non-typical SCLC histology. |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
<th id="tfxiq"><menuitem id="tfxiq"></menuitem></th>